MALVERN, Pa., Feb. 2 /PRNewswire-FirstCall/ -- Novavax, Inc.
(Nasdaq: NVAX) today announced the appointment of Rick A. Bright, Ph. D. to
the newly created position of Vice President, Vaccine Research. Dr. Bright
will report directly to Dr. Rahul Singhvi, President and CEO of Novavax.
"We are delighted to welcome Dr. Rick Bright to lead our Company's very
active vaccine research division," said Rahul Singhvi, President and CEO of
Novavax. "As a world-class immunologist, he complements our existing vaccine
leadership team consisting of Drs. Gale Smith, Steve Bandak and Craig Wright.
Rick's arrival at Novavax bolsters our efforts to develop a vaccine to fight
against a pandemic influenza and his decision is a further endorsement of our
virus-like particle (VLP) vaccine and Novasome(R) adjuvant technologies for
developing such a vaccine."
Dr. Bright, age 40, joins Novavax following more than 15 years' experience
as a researcher and expert on influenza vaccine and antiviral research, one of
a handful of such experts in the world. Most recently he has served at the
Centers for Disease Control (CDC) and Prevention in Atlanta, GA. Dr. Bright
worked in the Influenza Branch, Strain Surveillance Section, as Immunologist
and Virologist, Team Leader of the Antiviral Drug Program where he published
landmark papers on influenza antiviral drug resistance that led the CDC to
recommend against the use of two drugs for treatment of influenza infection.
Some of his recent work was rated in the top 10 infectious disease papers of
2005. Previously, Dr. Bright held the position of Senior Research Scientist
and Project Manager, Vaccine and Immunology Programs at Altea Therapeutics, a
biotech startup company in Atlanta, GA, directing the development of a new
generation of vaccines and improved delivery methods for vaccines.
From 1990 to 2002, Dr. Bright held various immunology and research
positions at the CDC and other research centers. Dr. Bright is on the cutting
edge of modern scientific research on influenza. His areas of expertise have
primarily included studies on pathogenicity and vaccine development for avian
H5N1 influenza viruses since the first human outbreak in 1997.
Dr. Bright received a Ph.D. in Immunology and Molecular and Viral
Pathogenesis, from the Division of Biological and Biomedical Sciences, School
of Medicine, from Emory University and B.Sc.'s in both Biology and Physical
Science from Auburn University-Montgomery. He is the author or co-author of
12 research articles, eight manuscripts in preparation and one patent. Dr.
Bright is affiliated with the American Biological Safety Association, American
Immunological Association, American Association for the Advancement of
Science, American Society of Virology, and the American Society of
Microbiology. He is also certified in Biosafety Level (BSL) 3+ high
containment laboratories and animal facilities, and has active federal
security clearance for select agent pathogens, including highly pathogenic
avian influenza viruses.
Dr. Bright added, "At the CDC, I was fortunate to be part of an excellent
and dedicated team of scientists working to combat the scourge of a potential
pandemic resulting from avian influenza. During this effort, I had the
opportunity to assess multiple vaccine and anti-viral approaches to control
and treat influenza. Novavax's recombinant VLP vaccine approach has the
potential to rapidly create effective vaccines against emerging human and
avian strains of influenza. In addition, this approach provides the
flexibility to incorporate the latest discoveries in immunology to truly
create best in class vaccines against a multitude of diseases. By joining
Novavax and its strong scientific team, I hope to realize my vision of
creating an effective and practicable vaccine against pandemic and seasonal
About Novavax, Inc.
Novavax, Inc. is a product development company focused on the research,
development and commercialization of products utilizing its proprietary drug
delivery and biological technologies for large and growing markets. Novavax's
drug delivery technologies include the micellar nanoparticle (MNP) technology
which is the basis for the development of its first FDA-approved product,
ESTRASORB. In addition to MNP, Novavax drug delivery technologies include
Novasomes(R) (paucillamellar non-phospholipid liposomes) and Sterisomes(R)
(subcutaneous depot injection). Novavax's vaccine technologies include its
virus-like particle (VLP) manufacturing technology utilizing the baculovirus
expression system in insect cells, as well as novel vaccine adjuvants based on
Novasomes and dendrimer technologies.
Statements made in this press release that state Novavax's or its
management's intentions, hopes, beliefs, expectations, or predictions are
forward-looking statements. Forward-looking statements include but are not
limited to statements regarding usage of cash, product sales, future product
development and related clinical trials and future research and development,
including FDA approval. Novavax's actual results could differ materially from
those expressed in such forward-looking statements. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of the
Company, or industry results, to be materially different from those expressed
or implied by such forward-looking statements. Such factors include, among
other things, the following: general economic and business conditions; ability
to enter into future collaborations with industry partners; competition;
unexpected changes in technologies and technological advances; ability to
obtain rights to technology; ability to obtain and enforce patents; ability to
commercialize and manufacture products; ability to maintain commercial-scale
manufacturing capabilities; results of clinical studies; progress of research
and development activities; business abilities and judgment of personnel;
availability of qualified personnel; changes in, or failure to comply with,
governmental regulations; the ability to obtain adequate financing in the
future through product licensing, co-promotional arrangements, public or
private equity financing or otherwise; and other factors referenced herein.
Additional information is contained in Novavax's annual report on Form 10-K
for the year ended December 31, 2004 and quarterly reports on Form 10-Q for
the quarters ended March 31, 2005, June 30, 2005 and September 30, 2005,
incorporated herein by reference. Statements made herein should be read in
conjunction with Novavax's annual and quarterly reports filed with the SEC.
Copies of these filings may be obtained by contacting Novavax at 508 Lapp
Road, Malvern, PA 19355, Tel 484-913-1200 or the SEC at http://www.sec.gov.
SOURCE Novavax, Inc.
CONTACT: Kathy Hamilton, Investor Relations, Novavax, Inc.,